177 filings
Page 4 of 9
F-3
MDNAF
Medicenna Therapeutics Corp.
17 Feb 23
Shelf registration (foreign)
4:47pm
SC 13G/A
MDNAF
Medicenna Therapeutics Corp.
15 Feb 23
Medicenna Therapeutics / HIRSCHMAN ORIN ownership change
6:35am
SC 13G/A
Merchant Fahar
14 Feb 23
Medicenna Therapeutics / Merchant Fahar ownership change
2:30pm
6-K
MDNAF
Medicenna Therapeutics Corp.
7 Feb 23
Interim condensed consolidated financial statements of
8:01am
6-K
MDNAF
Medicenna Therapeutics Corp.
31 Jan 23
Medicenna to Present at the 2023 Guggenheim Oncology Conference
8:50am
6-K
MDNAF
Medicenna Therapeutics Corp.
26 Jan 23
Current report (foreign)
7:15am
6-K
MDNAF
Medicenna Therapeutics Corp.
5 Jan 23
Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent
9:45am
6-K
MDNAF
Medicenna Therapeutics Corp.
10 Nov 22
Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting
9:05am
6-K
MDNAF
Medicenna Therapeutics Corp.
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
MDNAF
Medicenna Therapeutics Corp.
28 Oct 22
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
8:00am
6-K
MDNAF
Medicenna Therapeutics Corp.
25 Oct 22
Current report (foreign)
7:51am
SC 13G
Hirschman Orin
20 Oct 22
Medicenna Therapeutics / HIRSCHMAN ORIN ownership change
6:02am
6-K
MDNAF
Medicenna Therapeutics Corp.
17 Oct 22
Current report (foreign)
4:21pm
6-K
MDNAF
Medicenna Therapeutics Corp.
5 Oct 22
Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
8:28am
6-K
MDNAF
Medicenna Therapeutics Corp.
30 Sep 22
Current report (foreign)
8:22am
6-K
MDNAF
Medicenna Therapeutics Corp.
28 Sep 22
Current report (foreign)
9:45am
6-K
MDNAF
Medicenna Therapeutics Corp.
22 Sep 22
Current report (foreign)
4:42pm
6-K
MDNAF
Medicenna Therapeutics Corp.
22 Sep 22
Report of Voting Results
4:41pm
6-K
MDNAF
Medicenna Therapeutics Corp.
21 Sep 22
Medicenna Announces Results of Annual Meeting of Shareholders
5:10pm
6-K
MDNAF
Medicenna Therapeutics Corp.
13 Sep 22
Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial
4:38pm